DE69739105D1 - Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation - Google Patents
Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulationInfo
- Publication number
- DE69739105D1 DE69739105D1 DE69739105T DE69739105T DE69739105D1 DE 69739105 D1 DE69739105 D1 DE 69739105D1 DE 69739105 T DE69739105 T DE 69739105T DE 69739105 T DE69739105 T DE 69739105T DE 69739105 D1 DE69739105 D1 DE 69739105D1
- Authority
- DE
- Germany
- Prior art keywords
- survivin
- protein
- methods
- cellular apoptosis
- modulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000000763 Survivin Human genes 0.000 title abstract 10
- 108010002687 Survivin Proteins 0.000 title abstract 10
- 230000006907 apoptotic process Effects 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000037273 Pathologic Processes Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000031018 biological processes and functions Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000009054 pathological process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3143596P | 1996-11-20 | 1996-11-20 | |
PCT/US1997/021880 WO1998022589A2 (en) | 1996-11-20 | 1997-11-20 | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
US08/975,080 US6245523B1 (en) | 1996-11-20 | 1997-11-20 | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69739105D1 true DE69739105D1 (de) | 2008-12-24 |
Family
ID=26707241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69739105T Expired - Lifetime DE69739105D1 (de) | 1996-11-20 | 1997-11-20 | Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation |
Country Status (11)
Country | Link |
---|---|
US (7) | US6245523B1 (de) |
EP (1) | EP0950103B1 (de) |
JP (2) | JP4672092B2 (de) |
KR (1) | KR100645448B1 (de) |
AT (1) | ATE414149T1 (de) |
AU (1) | AU736587B2 (de) |
CA (1) | CA2271783C (de) |
DE (1) | DE69739105D1 (de) |
HK (1) | HK1027112A1 (de) |
IL (1) | IL130036A (de) |
WO (1) | WO1998022589A2 (de) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6365787B1 (en) | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
ATE414149T1 (de) * | 1996-11-20 | 2008-11-15 | Univ Yale | Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation |
US20030033621A1 (en) * | 1997-02-26 | 2003-02-13 | De La Monte Suzanne | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease |
US7226730B1 (en) * | 1997-02-26 | 2007-06-05 | The General Hospital Corporation | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease |
EP0975651A4 (de) * | 1997-02-26 | 2005-03-09 | Gen Hospital Corp | Transgene tiere und zellinien zur erkennung von zur behandlung oder vorbeugung der alzheimerschen krankheit wirksamen medikamente |
US6346389B1 (en) | 1998-04-01 | 2002-02-12 | Yale University | Method for selectively modulating the interactions between survivin and tubulin |
WO2000003693A1 (en) * | 1998-07-14 | 2000-01-27 | Jenner Biotherapies, Inc. | Survivin, and peptides thereof, as an anti-cancer vaccine |
AU2003205017B2 (en) * | 1998-09-29 | 2005-12-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
US6838283B2 (en) | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
US6077709A (en) * | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6773911B1 (en) | 1998-11-23 | 2004-08-10 | Amgen Canada Inc. | Apoptosis-inducing factor |
US6608108B2 (en) * | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
CA2392477A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
WO2001042449A2 (en) * | 1999-12-10 | 2001-06-14 | Anticancer, Inc. | Methods for introducing genes into mammalian subjects |
US6509162B1 (en) * | 2000-02-29 | 2003-01-21 | Yale University | Methods for selectively modulating survivin apoptosis pathways |
AU2001273102A1 (en) * | 2000-06-29 | 2002-01-14 | The Salk Institute For Biological Studies | Crystal structure of survivin |
CA2437305A1 (en) | 2001-01-12 | 2003-07-25 | Yale University | Detection of survivin in urine of bladder cancer patients |
US7776518B2 (en) | 2001-01-12 | 2010-08-17 | Yale University | Detection of survivin in the biological fluids of cancer patients |
DE10102722A1 (de) * | 2001-01-22 | 2002-08-14 | Medinnova Ges Med Innovationen | Verfahren und Testsystem zum Auffinden von Nervenzell-schützenden Substanzen |
WO2003061519A2 (en) * | 2002-01-18 | 2003-07-31 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US20040210035A1 (en) * | 2002-01-30 | 2004-10-21 | Straten Eivind Per Thor | Survivin-derived peptides and use thereof |
US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20040102395A1 (en) * | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of IAP-like expression |
EP1570080A4 (de) * | 2002-11-15 | 2006-03-01 | Genomic Health Inc | Genexpressionsprofilierung einer egfr-positiven krebserkrankung |
AU2003294540A1 (en) * | 2002-12-24 | 2004-07-22 | Saeid Babaei | Methods of diagnosing, preventing, and treating early onset of pulmonary hypertension |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
ES2529203T3 (es) | 2003-01-30 | 2015-02-17 | Survac Aps | Péptidos derivados de survivina y uso de los mismos |
CA2515096A1 (en) * | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
US7713738B2 (en) | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
AU2004213871B9 (en) * | 2003-02-20 | 2009-09-03 | Genomic Health, Inc. | Use of intronic RNA to measure gene expression |
MXPA05010255A (es) * | 2003-03-24 | 2005-12-14 | Scripps Research Inst | Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas. |
US20050164218A1 (en) * | 2003-05-30 | 2005-07-28 | David Agus | Gene expression markers for response to EGFR inhibitor drugs |
CA2524495A1 (en) * | 2003-06-03 | 2005-01-13 | Eli Lilly And Company | Modulation of survivin expression |
EP3470535B1 (de) | 2003-06-24 | 2020-04-01 | Genomic Health, Inc. | Vorhersage der wahrscheinlichkeit eines wiederauftretens von krebs |
US7526387B2 (en) * | 2003-07-10 | 2009-04-28 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
WO2005040396A2 (en) * | 2003-10-16 | 2005-05-06 | Genomic Health, Inc. | qRT-PCR ASSAY SYSTEM FOR GENE EXPRESSION PROFILING |
JP4926714B2 (ja) | 2003-11-19 | 2012-05-09 | サーバック エーピーエス | Bcl−2ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用 |
JP4718490B2 (ja) * | 2003-12-23 | 2011-07-06 | ジェノミック ヘルス, インコーポレイテッド | フラグメント化rnaの全般的増幅 |
DK2163650T3 (en) * | 2004-04-09 | 2015-11-02 | Genomic Health Inc | Genekspressionsmarkører for prediction of response to chemotherapy |
US20050260659A1 (en) * | 2004-04-23 | 2005-11-24 | Exagen Diagnostics, Inc. | Compositions and methods for breast cancer prognosis |
US7342093B2 (en) | 2004-07-23 | 2008-03-11 | University Of Massachusetts | Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins |
MX2007004176A (es) | 2004-10-06 | 2007-06-15 | Mayo Foundation | B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer. |
CA2585561C (en) * | 2004-11-05 | 2018-07-17 | Genomic Health, Inc. | Esr1, pgr, bcl2 and scube2 group score as indicators of breast cancer prognosis and prediction of treatment response |
HUE051605T2 (hu) * | 2004-11-05 | 2021-03-01 | Nsabp Found Inc | Kemoterápiára adott válasz elõrejelzése génexpressziós markereket alkalmazva |
NZ555645A (en) | 2004-11-09 | 2009-08-28 | Santaris Pharma As | LNA oligonucleotides and the treatment of cancer |
WO2006051075A1 (en) | 2004-11-12 | 2006-05-18 | Vib Vzw | Use of survivin to treat kidney failure |
KR20070086431A (ko) * | 2004-12-22 | 2007-08-27 | 더 지렛트 캄파니 | 서비빈 저해제를 이용한 모발 성장 감소 |
CN101111260B (zh) | 2005-02-04 | 2013-03-20 | 萨瓦克公司 | 存活蛋白肽疫苗 |
WO2006091666A2 (en) * | 2005-02-23 | 2006-08-31 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
US20060276423A1 (en) * | 2005-04-18 | 2006-12-07 | Rachel Altura | Survivin-directed RNA interference-compositions and methods |
PL1889065T3 (pl) | 2005-05-18 | 2013-12-31 | Novartis Ag | Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny |
US7272013B1 (en) * | 2005-07-28 | 2007-09-18 | American Megatrends, Inc. | Interchangeable design support system |
US7592330B2 (en) * | 2005-08-08 | 2009-09-22 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US20070049752A1 (en) * | 2005-08-23 | 2007-03-01 | Drysdale Neville E | Preparation of 2,6-dioxa-7-aza-bicyclo[2.2.2] octanes |
US7812173B2 (en) * | 2005-08-23 | 2010-10-12 | E.I. Du Pont De Nemours And Company | Tetrahydro-1,8-dioxa-4a-aza-naphthalenes in coating applications |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
WO2007082154A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
US20100015642A1 (en) * | 2006-01-05 | 2010-01-21 | Kwon Eugene D | B7-h1 and survivin in cancer |
WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
AU2007353412A1 (en) * | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
US9216080B2 (en) | 2007-08-27 | 2015-12-22 | Amo Groningen B.V. | Toric lens with decreased sensitivity to cylinder power and rotation and method of using the same |
US8974526B2 (en) * | 2007-08-27 | 2015-03-10 | Amo Groningen B.V. | Multizonal lens with extended depth of focus |
US8466140B2 (en) * | 2007-09-10 | 2013-06-18 | University Of Massachusetts | Mitochondria-targeted anti-tumor agents |
WO2009101202A1 (en) | 2008-02-15 | 2009-08-20 | Amo Regional Holdings | System, ophthalmic lens, and method for extending depth of focus |
US8439498B2 (en) | 2008-02-21 | 2013-05-14 | Abbott Medical Optics Inc. | Toric intraocular lens with modified power characteristics |
WO2009111315A2 (en) * | 2008-02-29 | 2009-09-11 | Mayo Foundation For Medical Education And Research | Methods for reducing granulomatous inflammation |
AU2009228146B2 (en) | 2008-03-28 | 2015-06-04 | Johnson & Johnson Surgical Vision, Inc. | Systems for ocular measurements |
CA2719964C (en) * | 2008-03-31 | 2016-10-04 | Bioimmulance Co., Ltd. | Partial peptide of survivin presented on mhc class ii molecule and use thereof |
US8862447B2 (en) | 2010-04-30 | 2014-10-14 | Amo Groningen B.V. | Apparatus, system and method for predictive modeling to design, evaluate and optimize ophthalmic lenses |
AU2010330809B2 (en) | 2009-12-18 | 2015-01-22 | Amo Groningen B.V. | Limited echelette lens, systems and methods |
US20130137642A1 (en) | 2010-04-23 | 2013-05-30 | Demetrios Vavvas | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
US20140024598A1 (en) | 2010-11-01 | 2014-01-23 | Demetrios Vavvas | Methods and compositions for preserving retinal ganglion cells |
US9817246B2 (en) | 2010-12-01 | 2017-11-14 | Amo Groningen B.V. | Multifocal lens having an optical add power progression, and a system and method of providing same |
US20140357570A1 (en) | 2011-10-21 | 2014-12-04 | Massachusetts Eye And Ear Infirmary | Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders |
WO2014087249A2 (en) | 2012-12-04 | 2014-06-12 | Amo Groningen B.V. | Lenses systems and methods for providing binocular customized treatments to correct presbyopia |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP2978450B1 (de) | 2013-03-27 | 2018-09-19 | ImmunoVaccine Technologies Inc. | Verfahren zur erhöhung der wirksamkeit eines survivin-impfstoffs zur behandlung von krebs |
US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
AU2014365888B2 (en) * | 2013-12-16 | 2018-12-06 | Merck Patent Gmbh | Survivin-directed cancer vaccine therapy |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
EP3242883A4 (de) | 2015-01-06 | 2018-10-17 | ImmunoVaccine Technologies Inc. | Lipid-a-mimetika, verfahren zur herstellung und verwendungen davon |
EP3291842A4 (de) * | 2015-05-07 | 2019-01-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Survivin-impfstoff variante zur behandlung von krebs |
WO2017041092A2 (en) * | 2015-09-04 | 2017-03-09 | Health Research, Inc. | Anti-survivin antibodies for cancer therapy |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
AU2016355926A1 (en) | 2015-11-18 | 2018-05-31 | Immunovaccine Technologies Inc. | Adjuvanting systems and water-free vaccine compositions comprising a polyi:C polynucleotide adjuvant and a lipid-based adjuvant |
CA3013858A1 (en) | 2016-02-09 | 2017-08-17 | Amo Groningen B.V. | Progressive power intraocular lens, and methods of use and manufacture |
EP3932368A1 (de) | 2016-03-23 | 2022-01-05 | Johnson & Johnson Surgical Vision, Inc. | Ophthalmische vorrichtung mit korrekturmeridianen mit erweitertem toleranzband |
EP3656350B1 (de) | 2016-03-23 | 2021-06-23 | Johnson & Johnson Surgical Vision, Inc. | Ophthalmische vorrichtung mit korrigierenden meridianen mit verlängertem toleranzband durch modifizierung der brechungskräfte in einheitlicher meridianverteilung |
US11060087B2 (en) * | 2016-06-15 | 2021-07-13 | The Regents Of The University Of California | Synthetic promoters for high throughput screening and gene modulation |
AU2017352030B2 (en) | 2016-10-25 | 2023-03-23 | Amo Groningen B.V. | Realistic eye models to design and evaluate intraocular lenses for a large field of view |
US10739227B2 (en) | 2017-03-23 | 2020-08-11 | Johnson & Johnson Surgical Vision, Inc. | Methods and systems for measuring image quality |
AU2018376564A1 (en) | 2017-11-30 | 2020-06-04 | Amo Groningen B.V. | Intraocular lenses that improve post-surgical spectacle independent and methods of manufacturing thereof |
FR3087448B1 (fr) | 2018-10-23 | 2023-10-13 | Pdc Line Pharma | Lignee pdc modifiee pour secreter une cytokine |
US11886046B2 (en) | 2019-12-30 | 2024-01-30 | Amo Groningen B.V. | Multi-region refractive lenses for vision treatment |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
US6238875B1 (en) * | 1991-03-12 | 2001-05-29 | The Scripps Research Institute | Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1 |
US6070969A (en) * | 1994-03-23 | 2000-06-06 | Hewlett-Packard Company | Thermal inkjet printhead having a preferred nucleation site |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
ATE414149T1 (de) * | 1996-11-20 | 2008-11-15 | Univ Yale | Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation |
US6346389B1 (en) * | 1998-04-01 | 2002-02-12 | Yale University | Method for selectively modulating the interactions between survivin and tubulin |
US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
US6509162B1 (en) * | 2000-02-29 | 2003-01-21 | Yale University | Methods for selectively modulating survivin apoptosis pathways |
US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
US6992063B2 (en) * | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
CA2437305A1 (en) * | 2001-01-12 | 2003-07-25 | Yale University | Detection of survivin in urine of bladder cancer patients |
WO2003039536A1 (en) * | 2001-11-07 | 2003-05-15 | Yale University | Enhancement of taxane-based chemotherapy by a cdk1 antagonist |
WO2004054516A2 (en) * | 2002-12-13 | 2004-07-01 | The Ohio State University | Antagonists for human prolactin |
US7342093B2 (en) * | 2004-07-23 | 2008-03-11 | University Of Massachusetts | Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins |
-
1997
- 1997-11-20 AT AT97949685T patent/ATE414149T1/de not_active IP Right Cessation
- 1997-11-20 EP EP97949685A patent/EP0950103B1/de not_active Expired - Lifetime
- 1997-11-20 AU AU73018/98A patent/AU736587B2/en not_active Expired
- 1997-11-20 WO PCT/US1997/021880 patent/WO1998022589A2/en not_active Application Discontinuation
- 1997-11-20 US US08/975,080 patent/US6245523B1/en not_active Expired - Lifetime
- 1997-11-20 CA CA2271783A patent/CA2271783C/en not_active Expired - Lifetime
- 1997-11-20 KR KR1019997004445A patent/KR100645448B1/ko not_active IP Right Cessation
- 1997-11-20 DE DE69739105T patent/DE69739105D1/de not_active Expired - Lifetime
- 1997-11-20 JP JP52400798A patent/JP4672092B2/ja not_active Expired - Lifetime
- 1997-11-20 IL IL130036A patent/IL130036A/en not_active IP Right Cessation
-
2000
- 2000-04-20 HK HK00102427.9A patent/HK1027112A1/xx not_active IP Right Cessation
- 2000-10-18 US US09/690,825 patent/US6943150B1/en not_active Expired - Lifetime
-
2002
- 2002-05-06 US US10/138,618 patent/US6800737B2/en not_active Expired - Lifetime
-
2005
- 2005-02-24 US US11/064,496 patent/US20050143308A1/en not_active Abandoned
- 2005-09-26 US US11/234,308 patent/US20060068453A1/en not_active Abandoned
- 2005-09-26 US US11/234,225 patent/US20060069025A1/en not_active Abandoned
-
2008
- 2008-12-24 JP JP2008328816A patent/JP2009073860A/ja active Pending
-
2009
- 2009-10-05 US US12/588,122 patent/US20110136743A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1027112A1 (en) | 2001-01-05 |
US20060069025A1 (en) | 2006-03-30 |
EP0950103B1 (de) | 2008-11-12 |
JP2002514060A (ja) | 2002-05-14 |
US20060068453A1 (en) | 2006-03-30 |
US6245523B1 (en) | 2001-06-12 |
IL130036A (en) | 2010-04-15 |
US6943150B1 (en) | 2005-09-13 |
IL130036A0 (en) | 2000-02-29 |
US20050143308A1 (en) | 2005-06-30 |
KR100645448B1 (ko) | 2006-11-13 |
JP2009073860A (ja) | 2009-04-09 |
US6800737B2 (en) | 2004-10-05 |
WO1998022589A2 (en) | 1998-05-28 |
ATE414149T1 (de) | 2008-11-15 |
US20030100525A1 (en) | 2003-05-29 |
EP0950103A2 (de) | 1999-10-20 |
AU7301898A (en) | 1998-06-10 |
US20110136743A1 (en) | 2011-06-09 |
WO1998022589A3 (en) | 1998-10-29 |
JP4672092B2 (ja) | 2011-04-20 |
KR20000057159A (ko) | 2000-09-15 |
CA2271783A1 (en) | 1998-05-28 |
CA2271783C (en) | 2013-04-16 |
AU736587B2 (en) | 2001-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69739105D1 (de) | Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation | |
NO962188D0 (no) | Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav | |
ATE393228T1 (de) | Fusionsproteine und deren verwendung zur messung von protease-aktivität | |
ATE318905T1 (de) | Homologe des tie-rezeptortyrosinekinase liganden | |
NZ323795A (en) | Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides | |
ATE332368T1 (de) | Selektion von proteinen mittels rns-protein fusionen | |
ATE470150T1 (de) | Methode zum schnellen identifizieren von kleinen organischen liganden | |
DE69833014D1 (de) | Menschliche toll homologen | |
DE60041452D1 (de) | CpG REZEPTOR (CpG-R) UND DARAUF BEZOGENE METHODEN | |
ATE311443T1 (de) | Methoden zur durchforstung (screenen) von proteinen | |
DK0948604T3 (da) | Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet | |
ATE212065T1 (de) | Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung | |
DK0862622T3 (da) | Fremgangsmåde til identifikation af forbindelser, der vekselvirker med RAC-proteinkinase | |
DE69532033D1 (de) | Für ein fibroblasten-aktivierungsprotein kodierende nukleinsäure und verwendungen dafür | |
ES2141249T3 (es) | Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores. | |
DK1082423T3 (da) | Cyclin E2-gener og -proteiner | |
DE69733861D1 (de) | Verwendung von neuronalem apoptose-inhibitorprotein | |
DK0871457T3 (da) | Isolerede stromaceller og fremgangsmåder til anvendelse heraf | |
DE69739346D1 (de) | Gereinigtes sr-p70 protein | |
ATE340257T1 (de) | Histonedeacetylase 9 | |
ES2178203T3 (es) | Metodos y reactivos para modular la apoptosis. | |
DE69734890D1 (de) | Rdgb-proteine | |
WO2003012103A3 (fr) | Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie | |
WO2003012102A3 (fr) | Acides nucleiques codant des proteines a domaine hect | |
AR009416A1 (es) | Nuevos genes que codifican proeinas de telomerasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |